16 November 2015 - According to the findings, an additional clinical benefit can be derived for different patient groups: in pretreated patients for whom ipilimumab is a suitable next treatment, severe and serious side effects as well as discontinuations due to side effects occur later under pembrolizumab. Overall, this results in an indication of a considerable added benefit.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/pembrolizumab-in-advanced-melanoma-added-benefit-for-certain-patients.7057.html